Truist Securities Maintains Hold on Globus Medical, Raises Price Target to $78
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter maintains a Hold rating on Globus Medical (NYSE:GMED) and raises the price target from $63 to $78.
July 16, 2024 | 1:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities analyst Richard Newitter maintains a Hold rating on Globus Medical and raises the price target from $63 to $78.
The raised price target from $63 to $78 indicates a positive outlook for Globus Medical, which could lead to a short-term increase in stock price. However, the Hold rating suggests that the stock may not outperform the market significantly.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100